75 citations
,
November 2009 in “Gynecological Endocrinology” This study found that both myo-inositol and metformin helped restore normal menstrual cycles in patients with PCOS, but myo-inositol appeared to be more effective in inducing pregnancy.
31 citations
,
September 2006 in “International journal of gynaecology and obstetrics” This article reviews diagnostic criteria and treatment options for polycystic ovary syndrome, focusing on hormonal and metabolic management strategies, and presents no new clinical data.
This article discusses the challenges of diagnosing and managing polycystic ovarian syndrome and reports no new research findings, emphasizing the need for improved diagnostic criteria and lifestyle intervention to prevent complications.
January 2026 in “Journal of Education Health and Sport” This review assesses whether using letrozole alongside physical activity and nutrition is clinically beneficial for enhancing ovulation outcomes in women with PCOS-related infertility, but it doesn't report specific results from the evaluation.
5 citations
,
October 2012 in “Journal of Midwifery & Women's Health” This article reviews infertility diagnosis and initial management for advanced practice clinicians, emphasizing the role of midwives and advanced practice nurses, but reports no new clinical findings.
17 citations
,
February 2004 in “PubMed” This review discusses symptom-driven treatment approaches for PCOS, focusing on ovulation induction, androgen reduction, and weight management, and reports recent advances like recombinant FSH and GnRH-agonist protocols without providing new clinical results.
2 citations
,
March 2011 in “Infertility” This review highlights that while lifestyle changes may help with many ovulatory disorders, oocyte donation is considered a viable option for patients who cannot undergo ovulation induction; it reports no new results.
4 citations
,
June 2007 in “PubMed” This review discusses current strategies for diagnosing and treating polycystic ovary syndrome and reports no new clinical results.
This article reviews the contraceptive agent Depo-Provera, discussing its effectiveness, potential side effects, and safety concerns, but reports no new clinical results.
18 citations
,
December 2014 in “Obstetrics and Gynecology Clinics of North America” This study suggests that weight loss can improve fertility outcomes in overweight and obese women with PCOS, and letrozole should be considered the new first-line treatment over clomiphene citrate for anovulatory infertility in this population.
5 citations
,
October 2022 in “Heliyon” This review discusses infertility in polycystic ovary syndrome and therapeutic options, without reporting new results; it underscores the importance of personalized treatment plans based on patient needs and disease characteristics.
3 citations
,
January 2018 in “Journal of South Asian Federation of Obstetrics and Gynaecology” This study compared letrozole and clomiphene citrate for ovulation induction in women with polycystic ovary syndrome and found that while clomiphene led to more follicles, monofollicular development and endometrial thickness were higher with letrozole, and pregnancy rates did not significantly differ between the two treatments.
11 citations
,
April 2013 in “Hormones” This article reviews recent data suggesting that metformin may be beneficial for anovulatory PCOS patients with normal BMI and clomiphene resistance but emphasizes that more studies are needed to confirm these findings.
2 citations
,
February 2022 in “Frontiers in Endocrinology” This study found that antiandrogenic pretreatment with combined oral contraceptives did not improve ovulation and pregnancy outcomes compared to direct letrozole induction in women with PCOS.
32 citations
,
July 2001 in “Endocrine Practice” This review discusses the therapeutic use of insulin-sensitizing agents in polycystic ovary syndrome, reporting improved ovulation, insulin sensitivity, and reduction of hyperandrogenism, but calls for larger studies to confirm these effects.
July 2023 in “Journal of Clinical Medicine” In this study, researchers investigated factors predicting resistance to clomiphene citrate in women with anovulatory PCOS, identifying AMH and SHBG levels as significant indicators, but they found no reliable thresholds for predicting resistance to the standard 50 mg/day dose.
7 citations
,
November 2003 in “Current Opinion in Obstetrics & Gynecology” This review summarizes recent studies on metformin for polycystic ovary syndrome, reporting its beneficial effects on endocrine, metabolic, and reproductive outcomes, but highlights ongoing debate about its mechanisms.
38 citations
,
October 2006 in “Fertility and Sterility” The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.
18 citations
,
March 2014 in “Current Pharmaceutical Biotechnology” This review discusses metformin's use in women with polycystic ovary syndrome, focusing on benefits during pre-conception and pregnancy, but reports no new clinical results.
11 citations
,
July 2003 in “The Nurse practitioner” This article reviews diagnostic and management strategies for polycystic ovary syndrome in primary care and reports no new clinical results; it also discusses when specialist referral is appropriate.
April 2024 in “Canadian Women s Health Today” This review suggests that "polycystic ovarian syndrome" is a misleading name, as the disorder involves complex metabolic and reproductive issues beyond ovarian dysfunction and may stem from factors affecting the fetus in utero.
7 citations
,
August 2017 in “European Journal of Obstetrics & Gynecology and Reproductive Biology” This study found that lower serum vaspin levels (below 3.74ng/mL) may predict successful ovulation induction with clomiphene citrate in anovulatory women with PCOS, indicating potential resistance when levels are higher.
1 citations
,
February 2017 in “Journal of gynecology and womens health” This review discusses the causes and management of hirsutism, recommending low-dose oral contraceptives with flutamide over cyproterone-containing preparations, but reports no new clinical findings.
6 citations
,
August 2023 in “Fertility and Sterility” This review details the 2023 International Guideline update for assessing and managing polycystic ovary syndrome, which provides evidence-based recommendations to improve care and patient outcomes but notes the remaining low to moderate quality of evidence.
January 2008 in “Humana Press eBooks” This article reviews the relationship between polycystic ovary syndrome and various health issues but provides no new clinical findings; it emphasizes the need for continued research and lifestyle interventions.
68 citations
,
January 2022 in “International Journal of Molecular Sciences” This review summarizes factors involved in polycystic ovary syndrome pathogenesis and management, highlights commonly prescribed and repurposed medications, and calls for well-designed clinical trials to evaluate these treatments further.
39 citations
,
September 2000 in “Obstetrics and Gynecology Clinics of North America” This article reviews evidence on hyperinsulinemia and insulin resistance in women with polycystic ovary syndrome and evaluates therapeutic responses to insulin-lowering agents, reporting no new clinical findings.
35 citations
,
January 2011 in “Clinical Endocrinology” Metformin should be used for PCOS mainly in those with glucose intolerance, and has limited benefits for infertility or hirsutism.
19 citations
,
October 2012 in “Frontiers of Hormone Research” This article reviews treatment strategies for ovulation induction in women with PCOS seeking pregnancy, emphasizing lifestyle changes and pharmacological options, and reports no new clinical findings.
89 citations
,
November 2014 in “Medical Clinics of North America” This article reviews management strategies for PCOS and reports no new clinical results; the authors highlight oral contraceptives, lifestyle modifications, and metformin as key interventions.